Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 7/20 | 0.55 |
| ▸ | GALR1 | P47211 | 6/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8256921 | 0.89 | GALR2 (0.56) | GALR2GALR1MAPK1POLBMAPT | |
| SCHEMBL6784994 | 0.88 | GALR2 (0.52) | GALR2GALR1HTR2CHTR2ASCN9A | |
| SCHEMBL8247745 | 0.87 | GALR2 (0.44) | GALR2GALR1TSHRALDH1A1LMNA | |
| SCHEMBL8263323 | 0.86 | GALR2 (0.59) | GALR2GALR1POLBMAPTHTR2C | |
| SCHEMBL8254470 | 0.83 | GALR2 (0.42) | GALR2GALR1TSHRALDH1A1KDM4E | |
| SCHEMBL3242747 | 0.83 | GALR2 (0.60) | GALR2GALR1MAPK1MAPTHTR2C | |
| SCHEMBL8256643 | 0.83 | MAPT (0.48) | GALR2GALR1TSHRALDH1A1LMNA | |
| SCHEMBL3247288 | 0.83 | GALR1 (0.55) | GALR2GALR1ALDH1A1LMNAMAPT | |
| SCHEMBL8256940 | 0.82 | MAPT (0.43) | GALR2GALR1TSHRALDH1A1LMNA | |
| SCHEMBL6797121 | 0.82 | GALR2 (0.54) | GALR2GALR1TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082587-A1 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | H. LUNDBECK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
| US-20040082587-A1 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | H. LUNDBECK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082587-A1 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | GALR3, GALR2, GALR1 | GALR2 2/4885GALR1 3/4885TSHR 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.